🇺🇸 FDA

Intelligence · Clinical Pipeline

Vertex Pharmaceuticals (Australia) Pipeline

All ClinicalTrials.gov programs at Vertex Pharmaceuticals (Australia) — phase, modality, and trial IDs.

Programs
61

Quick answer

Vertex Pharmaceuticals (Australia) has 61 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. ALPN-101

    Vertex Pharmaceuticals (Australia) Pty.

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  2. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  3. Cethrin

    Vertex Pharmaceuticals (Australia) Pty.

    Spinal Cord Injury

    phase 2 small molecule completed

    1 trial

  4. Inaxaplin

    Vertex Pharmaceuticals (Australia) Pty.

    Proteinuric Kidney Disease

    phase 2 small molecule active

    1 trial

  5. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial

  6. Ivacaftor 150 MG

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial

  7. Ivacaftor 25 mg/75 mg

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  8. MP-424 (Telaprevir)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  9. Merimepodib

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  10. P-1037

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  11. PLERIXAFOR, Casgevy 4 - 13 x 10^6 cells/mL dispersion for infusion, BUSULFAN

    Vertex Pharmaceuticals (Australia) Pty.

    Severe sickle cell disease (SCD)

    phase 2 small molecule active

    1 trial

  12. PREGABALIN, VX-993 tablet, VX-993 Placebo, VX-993 tablet, PREGABALIN, Pregabalin placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Pain Associated With Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  13. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  14. Placebo (matched to VX-121 suspension)

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  15. Povetacicept

    Vertex Pharmaceuticals (Australia) Pty.

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  16. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  17. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  18. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  19. Telaprevir and Sofosbuvir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  20. Tezacaftor/Ivacaftor + Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  21. VC-02 Combination Product

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 2 other completed

    1 trial

  22. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  23. VCH-759 (BCH-27759)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  24. VX-121

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  25. VX-135

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 2 small molecule completed

    3 trials

  26. VX-147

    Vertex Pharmaceuticals (Australia) Pty.

    Glomerulosclerosis, Focal Segmental

    phase 2 small molecule completed

    1 trial

  27. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials

  28. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Small Fiber Neuropathy

    phase 2 small molecule completed

    1 trial

  29. VX-150

    Vertex Pharmaceuticals (Australia) Pty.

    Osteoarthritis

    phase 2 small molecule completed

    1 trial

  30. VX-152

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  31. VX-222

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    2 trials

  32. VX-264

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  33. VX-264 Implant

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  34. VX-371

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Ciliary Dyskinesia

    phase 2 small molecule completed

    1 trial

  35. VX-371 + HS

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  36. VX-407

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    4 trials

  37. VX-407 tablet

    Vertex Pharmaceuticals (Australia) Pty.

    Autosomal Dominant Polycystic Kidney Disease (ADPKD)

    phase 2 small molecule active

    1 trial

  38. VX-522 mRNA therapy

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

  39. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Painful Lumbosacral Radiculopathy

    phase 2 small molecule completed

    1 trial

  40. VX-548

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    phase 2 small molecule completed

    2 trials

  41. VX-561

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule terminated

    2 trials

  42. VX-659

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  43. VX-661

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    2 trials

  44. VX-670

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy Type 1 (DM1)

    phase 2 small molecule active

    2 trials

  45. VX-670 Solution for Injection/Infusion

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  46. VX-670 Solution for Injection/Infusion, 0.9% saline solution (w/v)

    Vertex Pharmaceuticals (Australia) Pty.

    Myotonic Dystrophy

    phase 2 small molecule active

    1 trial

  47. VX-702

    Vertex Pharmaceuticals (Australia) Pty.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  48. VX-765

    Vertex Pharmaceuticals (Australia) Pty.

    Partial Epilepsy

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Vertex Pharmaceuticals (Australia) have?

61 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.